



**Current as of August 15, 2024**

**Keyword Index**

#

3D heterotypic models B045, B046

**A**

Abdomen A008

Aberrant Glycosylation B037

ABO blood group A024

Acinar cells B022

Acinar plasticity C059

acinar to ductal metaplasia C064

Acinar-to-Ductal Metaplasia A081

adaptive resistance C012

Adeno-associated virus (AAV) A069

Adenosine C007

ADM C079

adoptive T cell transfer C020

advanced pancreatic cancer B012

albumin-bound drugs C022

Alcoholic Chronic Pancreatitis A051

AlphaFold A021

Alternative splicing B083

amino acid therapy A020

antibody C019

Antigen presentation B063

APE1 C028

apoptosis C032

artificial intelligence B066

ATAC-seq C056

ATF3 B082

ATM A055, B088

Autophagy IA-01, IA-06, A001, B006, C023, C026,  
 C036, C047

**B**

B cell B047

B cells B040

Basal C060, PR-21



basal cells	B068
Basal-like	A077
basal-like PDAC	C063
beta catenin	C025
beta-cells	B010, PR-05
β-lapachone	A070
beta-tubulin	A079
Bigdata	A071
Bioactive	A085
Bioinformatics	B028, PR-14, B032
biomarker	B021
Biomarker	A071, B070, C005
biomarkers	B018, B023
Biomarkers	A033, B011, B079, C070
black race	A019
Bmi1	C072
Body wasting	IA-09
BRCA	B029
BRCA1	A080
BRCA2	A080
<b>C</b>	
CA 19-9	A019
cachexia	IA-09, B001, B005, B006, B007, B011, B013, B014
CAF	A037, B071
CAF subtype	A042
CAFs	A060
CaMK2B	C061
Cancer associated fibroblast	A032, A039, A041, A047, A048, B041, B075, C042
Cancer associated fibroblast heterogeneity	IA-03
cancer cell plasticity	C077
Cancer Plasticity	C074
cancer progression	A075
cancer stem cells	B086
Cancer-neuroscience	A041
Cannabis	B031
CAR T cells	B037
CAR T-cells	B060



Case-control	B020
CD-155	B054
CD73	C007
CD8 T cells	B058
CD8+ T cells	IA-02, C048, PR-20
cDC1 vaccine	B064
CDK1	A011
CDK12	A084
CEACAM1	C005
Cell adhesion	A033
cell of origin	A025
Cell Plasticity	C075
cell polarity proteins	C051, PR-19
cell signaling	A072
Cellular Plasticity	C067
Centroacinar cell	A068
ceramide	A066
Checkpoint	B058
Checkpoint inhibitor	B053
Checkpoint Inhibitors	B062
chemoradiation	B078
chemoresistance	C031
Chemosensitivity	A010
Chemotherapy	B049, C001
chemotherapy response and resistance	C009, PR-17
Chromatin	C056
Chromatin Accessibility	C078
circadian	B087, PR-12
circadian rhythm	B057
circulating tumor DNA	A009
Classical	C060, PR-21
clinical trial	B061, PR-10
Clinical Trial	A001
clinical trials	B066
Collagen Hydrogels	A054
collagen type I	A035
collagens	A049
combinations	IA-04
Combination therapy	C046



Combinatorial treatment	C021, PR-15
COMPASS-like complex (CLC) gene	A040
Complete regression	C011
Cori cycle	IA-09
CREB	A051
CRISPR screen	B060
CRIS PR-directed gene editing	A010
Crosstalk	A036, A037
Cryptic antigens	B056, PR-07
ctDNA	B021
Cyclic immunofluorescence	B024
Cysteine	C037
Cytokine mRNA Platform	B059

## D

DDR1	A049
Dec2	B087, PR-12
Deep Learning	C065
Desmoglein-2	A073
diet	B009, PR-06
Diet	B004
Digestive protease,	B054
digital droplet polymerase chain reaction	A009
digital PCR	B029
dihydroorotate dehydrogenase	C031
disease risk	C058
DNA	C028
DNA methylation	B020
DNA repair	A003, PR-04
dormancy	B087, PR-12
drug resistance	C077
Drug resistance	B089, C024
Drug resistance, Nutrient transporters, MAPK pathway	C017
Drug Sensitivity Analysis	A023
drug testing	B093
drug vulnerabilities	C066

## E

early detection	B018, B023
Early detection	B019



Early Detection	B027
early detection of PDAC	B026
early neoplasia	C056
early pancreatic cancer detection	B025
EGFR, RAF1, STAT3	C011
EMT	C073
EMT plasticity	B091
Endocrine-exocrine crosstalk	C043
Endothelial cells (EC)	B074
enhancer	C058
Entropy	A053
Eosinophils	B065
Epigenetic	A058
Epigenetics	B062, B082, C072, C078
epistasis	C015
Epistasis	C030
ERK	IA-05
ER stress	A018
ER stress responses	C039
Evolution	C030
exosomes	A066
extracellular vesicles	A075
Extracellular vesicles	C034
EZH2	B088
<b>F</b>	
familial pancreatic cancer	B025
ferroptosis	B009, PR-06
Ferroptosis	B085, C018
fibrin	B072
fibroblast	A044
fibroblasts	A050, A063
Fibroblasts	A053, A064, PR-03
fibrosis	B067, PR-09
First-line Therapy	C054
FixNCut	C079
Flavonoid	B031
FOLFIRINOX	A012, A067
FOLFIRINOX versus gemcitabine plus nab-paclitaxel	C054
FRA1	C064



functional genetics A016

## G

gamma-aminobutyric acid C042  
Gemcitabine resistance C034  
Gemcitabine Resistance C052  
gemcitabine/cisplatin/nab-paclitaxel B012  
gene expression B093, C057  
gene signature A013  
Genetically Engineered Mouse (GEM) models A069  
genetically engineered mouse model C061  
Genetics C055  
GENIE C054  
genomics C058  
GeoMx B073  
germinal center B047  
Glutathione C037  
gMDSC B050  
Golgi pH C041  
GSK3B inhibition C073  
GWAS A018

## H

health disparities C076  
Hepatic artery chemotherapy C004  
heterogeneity A028, A044  
Heterogeneity A046, A053  
HIF-2 B085  
High-Density Collagen I A035  
high-throughput screen C066  
Homologous recombination deficiency A031  
host B013  
HR repair pathway C046  
HRD C006  
HRDsig C006  
Hyperpolarized MRI B019  
Hypoxia A036, A037, A038, B036, C038  
Hypoxia B085, C039

## I



Immunogenic cell death	A070
iCAF	B050
iCAF & myCAF fibroblasts	A030
ICI	B071
IDH1	C046
Imaging mass cytometry	A032
immune	A022
Immune clearance	B044
Immune evasion	A076
Immune infiltration	B045, B046
immune microenvironment	A034, B035
Immune Oncology	B059
immune recognition	B057
Immune stimulation	A005, PR-01
immunology	A066
Immunology	B038
Immuno-modulation	B048
Immuno-oncology	B032
Immuno-peptidome	B063
Immuno-peptidomics	B056, PR-07
Immunosuppression	B051, C007
immunotherapy	B043, B055, C002
Immunotherapy	A004, A031, A052, B033, B038, B058, C001
In vivo CRISPR screening	C021, PR-15
inflammation	B014
Inflammation	B022
Interleukin 6	B044
Interleukin-1	A047
Interstitial Fluid	IA-09
Intraductal Papillary Mucinous Neoplasm (IPMN)	B091
intravasation	A059
Intravital imaging	B067, PR-09
invasion	C069
Invasion	C070
IPMN	B015, C030
IRE1	C040, PR-18
Iron homeostasis	C044
Iron metabolism	IA-01
isogenic models	C066



**J**

There were no keywords in this range.

**K**

keratin 17	C031
Keratin 17	B079
ketogenic diet	B012
kinase signaling networks	A049
kinome specificities	A072
KPC cells	A035
kras	C025
KRAS	IA-05, IA-08, A001, A002, A034, B082, C010, C013, PR-16, C015, C020, C026, C027, C036
KRAS G12D	C012
KRAS G12D inhibition	C024
KRAS inhibitor	C029
KRAS inhibitor resistance	C013, PR-16
KRAS inhibitors	C021, PR-15
KRAS Q61H inhibitor	C013, PR-16
KRAS, therapy resistance, pancreatitis	C016
KRAS,TP53	B080
KrasG12D	C064
KRASG12D	B008
KRASi	C018
KRAS-mutant pancreatic cancer	C012
KSR1	A002

**L**

Large Language Models	A029
lenvatinib	C002
Lfng	A068
LINE-1	A076
Lipid	IA-09, C033
Lipid Imbalance	C039
lipid nanoparticles	B035
Lipopolysaccharide	B048
Liquid biopsy	B015
Liver	B030, PR-08





local immunosuppression	A045
Localized PDAC	C004
Long-read sequencing	A083
Lymph node	B040
LysolP-based proteomic	A082
Lysosome	IA-01, C033

**M**

machine learning	B066
machine learning classifier	B026
macrophage	B043
Macrophages	A038, B051
macropinocytosis	IA-06, B092, C022, C051, PR-19
MAGEA6-expressing cells, MIA PaCa-2 pancreatic cancer cells, 2-deoxy-D-glucose (2-DG)	C035
maintenance therapy	B061, PR-10
malignancy	C069
Malignant cell-fibroblast crosstalk	IA-03
MDSC	C068
mdscs	A050
MEK inhibition	C023
MEK inhibitor	C029
Metabolic analysis	C049
Metabolic crosstalk	A065
metabolic diseases in PDAC patient	C043
Metabolic Imaging	B019
metabolic stress	C051, PR-19
metabolism	B009, PR-06
Metabolism	B006, C038, C048, PR-20, C052
Metabolism	B004
Metabolome	B036
Metaplasia	B022
metastasis	A074, B007, B072, B076, C029, C061
Metastasis	B030, PR-08, B040, B065, B073, B079
methylation	A014
mFOLFIRINOX	A012
MHC-1	B054
MICAL2	A052
microenvironment	A042
Microenvironment	A046, C038, C065



micronuclei	A084
microRNA	B005
Migration	A030
Mitochondria	B017, PR-13
mitotic catastrophe	A084
molecular biology	A016
molecular subtyping	A048
Morphology	B076
Mouse model	A006
mouse models	A025
Mouse models	A031
MPRA	A018
MTAP deficiency	A028
MUC1	C034
MUC16	B033, B051
MUC5AC	A015
mucins	A075
mutation	IA-07
Multiplex	A006
muscle microenvironment	B005
Mutual exclusivity	B077, PR-11
Myc	IA-05, A078
Myc expression	C067
Myeloid cells	A051
Myeloid Cells	B062
Myeloid Derived Suppressor Cells	A047
myeloid immunotherapy	B061, PR-10
Myeloperoxidase	B034
<b>N</b>	
Nectin-4 dimer	A085
Neighborhoods and microenvironment	B081
neoadjuvant	B013
neoantigen	B042, B047
neoepitopes	IA-02
NET	A065
Neuroendocrine	B032
Neurotropism	A062
Neutrophil	A065, B030, PR-08
neutrophils	A050




Neutrophils	C068
NF-kappaB	B014
Niraparib	A003, PR-04
Notch	A064, PR-03
Notch signaling	A068
Novel Therapeutics	B049
NRF2	A010

**O**

obesity	B003, B010, PR-05
Oncogene	A061
Oncogenic competence	C059
Oncology	B038
Oncolytic virus	B049
Oncopig	B080
One-carbon metabolism	C050
organoid	B086
Organoid	A058, A081
organoid models	B075
Organoids	A057, C008
origin	A044
Oxidative stress	B060, C037
OXPPOS	C040, PR-18

**P**

Precision Medicine	C008
predictive biomarker	A014
P2X receptors	C041
p53	B084
P53 reactivation	A026
pancreas	C025
Pancreas	C027
Pancreas adenocarcinoma	C048, PR-20
Pancreas Cancer	A004, A057
Pancreas development	C059
pancreatic adenocarcinoma	A059, B029
Pancreatic adenocarcinoma, Aging	A033
Pancreatic cancer	IA-08, IA-09 A013, A014, A015, A020, A024, A083, B007, B057, B086, C003, C047, A009, A021, A027, A039, A056,



AACR Special Conference on  
**Advances in Pancreatic  
 Cancer Research**

September 15-18, 2024 | Boston, MA



2404022E

A077, B004, B015, B033, B034, B063,  
 B081, B088, B089, C005, C019, C050,  
 C060, PR- 21, A029, A054, C042

Pancreatic Cancer Immunotherapy	B056, PR-07
Pancreatic cancer precursors	B028, PR-14
pancreatic cancer surveillance	B025
Pancreatic Cancer-associated Weight Loss	B001
pancreatic ductal adenocarcinoma	A025, A048
Pancreatic ductal adenocarcinoma	A017, A076
Pancreatic Ductal Adenocarcinoma	A005, PR-01
Pancreatic ductal adenocarcinoma (PDAC)	A023, A069
Pancreatic Ductal Adenocarcinoma (PDAC)	B059
Pancreatic Neoplasia and Adenocarcinoma	C075
pancreaticoduodenectomy	B003
Pancreatitis	C079
Pancreatitis and PDAC	B024
Pancreatitis in PDAC	B064
PanIN	A081
pan-RAS	C027
paracrine signaling	A045
PARG	B024
PARP inhibitor	A003, PR-04
pathologic response	A019
Patient response prediction	C053
Patient-derived organoids	C053
Patient-derived organoids (PDOs)	A023
PDAC	A007, PR-02, A011, A012, A030, A055, A060, A067, A074, A078, A079, A082, B027, B041, B071, B080, B084
PDAC immunity	B052
PDAC Stroma TME	B037
PDAC, Cachexia, PTHrP	B002
PDACs 3D cell culture	B093
PD-L1	A007, PR-02
pembrolizumab	C002
Pepinemab	A004
Pericytes (PC)	B074
perioperative	C003
PET Imaging	B016
pH homeostasis	C041




phosphoproteomics analysis	A072
Photochemical internalisation	A027
Photosensitizer	A027
PI5P4K	C044
PIKfyve	B092, C026, C033
plasma	IA-09
plasticity	C071, C076
Plasticity	C070
Platinum therapy	A080
postoperative outcomes	B003
PP2A	B092
Pre-cancer	B017, PR-13
precision medicine	C015
Preclinical to clinical translation	IA-04
Preclinical tools	C053
Pre-diagnostic serum	B020
Predictive biomarkers	IA-09
pre-existing immunity	B055
premetastatic niche	A063
Primary CAFs	A058
PRMT5	C063
progression	C069
Proline metabolism	C047
Protein	B027
Proteomics	C071
PTEN	A060
pyrimidine	C032

## Q

Quantitative proteomics	C024
-------------------------	------

## R

racial disparity	C057
Racial disparity	A007, PR-02
Racial Health Disparities	B090
Radiation	A022
Radioresistance	A011
Radiotherapy	B031
RAF Inhibitor	A002
RAS	IA-06, IA-07



RAS inhibitors	C022
RAS(ON) Inhibition	IA-04
Reactive oxygen species	A026
recurrence	A015
Regulation	C055
Repeat RNA	A039
resistance	B076
Resistance	A067, C011, C018, C023
Retrospective	B011
RhoV	A021, A077
RNA splicing	B077, PR-11, C057, C063
RNA translation	A078
RNAseq	A022
RNF2	B090
RNF43	C040, PR-18
Ror2	C075
Rucaparib	C006

**S**

synergy	C032
Safety and efficacy	C004
SB-216	A079
SCENIC	B050
scRNAseq	A062, B068
selective toxicity	A020
senescence	B035
Senescence	B016
SF3B1 and RBM10	B077, PR-11
Signaling	A073
Simulations	A008
Single cell RNA sequencing	A057
single cell RNA sequencing, spatial transcriptomics	B052
single cell transcriptomics	B078
Single Nucleus RNA sequencing	B001
single-cell RNA (scRNA)	C074
Single-Nucleus Genomics	A029
Somatic tissue engineering	A006
Spatial -omics	B081
Spatial Sequencing	C065
Spatial Transcriptomic analysis	B091



Spatial transcriptomics	B028, PR-14, B078
Spatial Transcriptomics	A046
STAT3	A063, B041
Statins	C052
stem-cell derived organoids	C010
stress	B010, PR-05
Stress	C072
Structural variations	A083
Subtype	B090, C076
subtype classifier	A042
Sulfatides	B017, PR-13
sumoylation	B043
SUMOylation inhibition	B053
survival	A024, A074
Survival motor neuron domain containing 1 (SMNDC1)	B083
Sympathetic Nerves	A041
Syndecan	IA-08
Syndecan-1	C019
Systemic metabolism	IA-09
Systems biology	C049
<b>T</b>	
T cell	B055
T cell receptor	B042, C020
T cells	A032, B044
Targeted Alpha Radiotherapy	B016
Targeted RNA Delivery	A005, PR-01
Targeted therapy	A026
T-Cells	A036
TGFB2	B070
TGF- $\beta$	C001
TGF- $\beta$ signaling	B075
TGFbeta, NFAT5, S100A4	C016
Therapeutic combination	B045, B046
Therapeutic effects	A017
Therapeutics	C008
Therapy	B089
Therapy resistant	B083
TIGIT	B053
TIGIT binding	A085



tissue microarray	A028
TLR-4 Agonism	B048
TME	B068
TMEM doorway	A059
transcription factors	C071
transcriptomic subtypes	C009, PR-17
Treatment	C028
treatment selection	A013
Tuft cells	C067
tumor evolution	C077
tumor heterogeneity	C045
Tumor Heterogeneity	C078
Tumor immune microenvironment	B073
tumor immunology	A034
Tumor initiation	IA-07
tumor metabolism	C045
tumor metabolism	C043
tumor metastasis	A082
tumor microenvironment	IA-03, A040, A045, B072, A052, A055, B070, A064, PR-03, A056, C068, A062, B074, C074
tumor niche	C010
tumor progression	B084
Tumor suppressor	A061
tumor treating fields	C003
Tumor Treating Fields	A008
tumor-associated antigen	IA-02, B042
Tumor-associated macrophages	B036
Tumor-associated neutrophils	B034
tumor-reactive T cells	B052
Tumor-stroma crosstalk	A061
tumour microenvironment	B067, PR-09
Tumour Microenvironment	A054
Tumour microenvironment	A073
Twist1, Cachexia, PDAC	B008
<b>U</b>	
ULK	C036
Urinary miRNA	B026
urine	B018





**V**

VHH	A071
Vimentin	A070
Vitamin B6	C050
VNTR	C055

**W**

Whole genome sequencing	C009, PR-17
Whole-body hyperthermia	A017

**X**

There were no keywords in this range.

**Y**

There were no keywords in this range.

**Z**

There were no keywords in this range.